Endoscopic sinus surgery versus biologic therapy for chronic rhinosinusitis with nasal polyposis: a systematic review with meta-analysis
Volume: 0 - Issue: 0
First page: 0 - Last page: 0
H. Majeethia - Z. Mehdi - O.G. Ahmed - M. Takashima - G.A. Kelley - J. Lee - H.H. Ramadan - C.A. Makary
DOI: 10.4193/Rhin25.345
Biologic therapies targeting type 2 inflammation, such as dupilumab, omalizumab, and mepolizumab, have been developed to manage chronic rhinosinusitis with nasal polyps (CRSwNP), particularly in patients with comorbid asthma or aspirin-exacerbated respiratory disease (AERD). Functional endoscopic sinus surgery (FESS) remains the mainstay of treatment in patients who are refractory to medical therapy. However, direct comparisons between biologic therapy and FESS are limited. This systematic review and meta-analysis aimed to compare sinonasal outcomes between FESS and biologic therapy in real-world settings.
Rhinology 0-0: 0-0, 0000
To see the issue content and the abstract you do not have to login
Please login to download the full articles
If you do not have a subscription to Rhinology please consider taking one.
